Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:13 PM
Ignite Modification Date:
2025-12-24 @ 10:13 PM
NCT ID:
NCT03841435
Eligibility Criteria:
Inclusion Criteria:
1. Patients must be ≤30 years of age
2. Patients must have a diagnosis of progressive DIPG.
3. Received prior IMRT based definitive radiotherapy to a dose of ≥54 Gy.
4. The patient and or parent/legal guardian must be physically and mentally capable of signing the consent form of their own volition.
5. Steroids dosage must be unchanged for 5 days.
6. No Bevacizumab within 21 days (Half-life 11 days \~)
Exclusion Criteria:
1. Patients with incomplete medical records
2. Patients with prior history of reirradiation for DIPG
3. Life expectancy \< or equal to 1 month
4. Pregnant women
5. Age \>30
6. Prisoners
7. Concurrent systemic therapy at the time of reirradiation
8. Physically or mentally incapable of signing the consent form of their own volition
9. \< 6 mos time interval between completion of initial RT to start of reRT.
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
30 Years
Study:
NCT03841435
Study Brief:
Protocol Section:
NCT03841435